(Q36478120)

14 August 2017

1 reference

title

Established and emerging therapies for the treatment of viral hepatitis (English)

1 reference

14 August 2017

Daniel Forton

1

1 reference

14 August 2017

Peter Karayiannis

series ordinal

2

1 reference

14 August 2017

publication date

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

24

1 reference

14 August 2017

issue

1-2

1 reference

14 August 2017

page(s)

160-173

1 reference

Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B.

14 August 2017

cites work

1 reference

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

21 January 2018

1 reference

Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B.

21 January 2018

1 reference

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

21 January 2018

1 reference

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

21 January 2018

1 reference

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

21 January 2018

1 reference

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

21 January 2018

1 reference

Four years of lamivudine treatment in Chinese patients with chronic hepatitis B.

21 January 2018

1 reference

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

21 January 2018

1 reference

Durability of serologic response after lamivudine treatment of chronic hepatitis B.

21 January 2018

1 reference

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

21 January 2018

1 reference

Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy.

21 January 2018

1 reference

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

21 January 2018

1 reference

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

Long-term therapy of chronic hepatitis B with lamivudine.

21 January 2018

1 reference

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

21 January 2018

1 reference

Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection

21 January 2018

1 reference

Two years of lamivudine therapy in anti-HBe-positive patients with chronic hepatitis B.

21 January 2018

1 reference

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

21 January 2018

1 reference

Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis

21 January 2018

1 reference

Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation

21 January 2018

1 reference

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

21 January 2018

1 reference

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

21 January 2018

1 reference

Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection

21 January 2018

1 reference

High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation

21 January 2018

1 reference

Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation

21 January 2018

1 reference

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

21 January 2018

1 reference

Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens

21 January 2018

1 reference

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

21 January 2018

1 reference

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

21 January 2018

1 reference

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase

21 January 2018

1 reference

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus

21 January 2018

1 reference

Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study

21 January 2018

1 reference

Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial

21 January 2018

1 reference

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study

21 January 2018

1 reference

Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study

21 January 2018

1 reference

Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine

21 January 2018

1 reference

A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection.

21 January 2018

1 reference

A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.

21 January 2018

1 reference

Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection

21 January 2018

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

21 January 2018

1 reference

Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection

21 January 2018

1 reference

Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV.

21 January 2018

1 reference

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

21 January 2018

1 reference

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

21 January 2018

1 reference

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine

21 January 2018

1 reference

Quasispecies, error catastrophe, and the antiviral activity of ribavirin

21 January 2018

1 reference

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C.

21 January 2018

1 reference

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

Diagnosis, management, and treatment of hepatitis C

21 January 2018

1 reference

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

21 January 2018

1 reference

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

21 January 2018

1 reference

Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial

21 January 2018

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

Treatment of acute hepatitis C with interferon alfa-2b

21 January 2018

1 reference

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

21 January 2018

1 reference

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

21 January 2018

1 reference

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

Role of amantadine and other adjuvant therapies in the treatment of hepatitis C.

21 January 2018

1 reference

Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection.

21 January 2018

1 reference

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.

21 January 2018

1 reference

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

21 January 2018

1 reference

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

21 January 2018

1 reference

Hepatitis B genotypes and the response to interferon therapy

21 January 2018

1 reference

Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

21 January 2018

1 reference

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

21 January 2018

1 reference

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C in naive patients: 1999 Update

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000090319

1 reference

14 August 2017

1 reference